BELITE BIO INC - ADR (BLTE) Fundamental Analysis & Valuation

NASDAQ:BLTE • US07782B1044

Current stock price

169.85 USD
+2.6 (+1.55%)
At close:
169.85 USD
0 (0%)
After Hours:

This BLTE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BLTE Profitability Analysis

1.1 Basic Checks

  • In the past year BLTE has reported negative net income.
  • In the past 5 years BLTE always reported negative net income.
  • BLTE had a negative operating cash flow in each of the past 5 years.
BLTE Yearly Net Income VS EBIT VS OCF VS FCFBLTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • BLTE has a Return On Assets (-32.42%) which is comparable to the rest of the industry.
  • With a decent Return On Equity value of -33.75%, BLTE is doing good in the industry, outperforming 60.94% of the companies in the same industry.
Industry RankSector Rank
ROA -32.42%
ROE -33.75%
ROIC N/A
ROA(3y)-28.59%
ROA(5y)-32.16%
ROE(3y)-30.08%
ROE(5y)-34.27%
ROIC(3y)N/A
ROIC(5y)N/A
BLTE Yearly ROA, ROE, ROICBLTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BLTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLTE Yearly Profit, Operating, Gross MarginsBLTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BLTE Health Analysis

2.1 Basic Checks

  • BLTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLTE Yearly Shares OutstandingBLTE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BLTE Yearly Total Debt VS Total AssetsBLTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • BLTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BLTE Yearly LT Debt VS Equity VS FCFBLTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 24.31 indicates that BLTE has no problem at all paying its short term obligations.
  • BLTE has a better Current ratio (24.31) than 93.23% of its industry peers.
  • A Quick Ratio of 24.31 indicates that BLTE has no problem at all paying its short term obligations.
  • The Quick ratio of BLTE (24.31) is better than 93.23% of its industry peers.
Industry RankSector Rank
Current Ratio 24.31
Quick Ratio 24.31
BLTE Yearly Current Assets VS Current LiabilitesBLTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BLTE Growth Analysis

3.1 Past

  • BLTE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.92%.
EPS 1Y (TTM)-94.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BLTE will show a very strong growth in Earnings Per Share. The EPS will grow by 65.39% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.26%
EPS Next 2Y7.48%
EPS Next 3Y55.87%
EPS Next 5Y65.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLTE Yearly Revenue VS EstimatesBLTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
BLTE Yearly EPS VS EstimatesBLTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

1

4. BLTE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BLTE. In the last year negative earnings were reported.
  • Also next year BLTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLTE Price Earnings VS Forward Price EarningsBLTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLTE Per share dataBLTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • BLTE's earnings are expected to grow with 55.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.48%
EPS Next 3Y55.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLTE Dividend Analysis

5.1 Amount

  • BLTE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLTE Fundamentals: All Metrics, Ratios and Statistics

BELITE BIO INC - ADR

NASDAQ:BLTE (4/2/2026, 4:30:01 PM)

After market: 169.85 0 (0%)

169.85

+2.6 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners18.61%
Inst Owner Change263.54%
Ins Owners1.21%
Ins Owner Change0%
Market Cap6.37B
Revenue(TTM)N/A
Net Income(TTM)-49.28M
Analysts84.29
Price Target215.73 (27.01%)
Short Float %4.86%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.07%
Min EPS beat(2)-30.72%
Max EPS beat(2)-17.41%
EPS beat(4)0
Avg EPS beat(4)-17.04%
Min EPS beat(4)-30.72%
Max EPS beat(4)-1.93%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)4
Avg EPS beat(12)-15.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.24%
PT rev (3m)14.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.72%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 43.74
P/tB 43.74
EV/EBITDA N/A
EPS(TTM)-2.3
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.88
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.42%
ROE -33.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.59%
ROA(5y)-32.16%
ROE(3y)-30.08%
ROE(5y)-34.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.31
Quick Ratio 24.31
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)261.74%
Cap/Depr(5y)203.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.75%
EPS Next Y45.26%
EPS Next 2Y7.48%
EPS Next 3Y55.87%
EPS Next 5Y65.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.62%
EBIT Next 3Y93.09%
EBIT Next 5Y91.2%
FCF growth 1Y1.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.02%
OCF growth 3YN/A
OCF growth 5YN/A

BELITE BIO INC - ADR / BLTE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BELITE BIO INC - ADR (BLTE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BLTE.


Can you provide the valuation status for BELITE BIO INC - ADR?

ChartMill assigns a valuation rating of 1 / 10 to BELITE BIO INC - ADR (BLTE). This can be considered as Overvalued.


Can you provide the profitability details for BELITE BIO INC - ADR?

BELITE BIO INC - ADR (BLTE) has a profitability rating of 1 / 10.